Pheochromocytoma: The Catecholamine Storm and the Rule of 10s

What It Is and Why It Matters

A pheochromocytoma is a catecholamine-producing neuroendocrine tumor arising from chromaffin cells of the adrenal medulla — the same cells that normally release epinephrine into the bloodstream during the fight-or-flight response. When the tumor secretes autonomously and episodically, it produces the paroxysmal hypertension and adrenergic crises that make it feared out of proportion to its rarity.

Why it matters clinically:

• It is a surgically curable cause of hypertension — removing the tumor can normalize blood pressure permanently.
• Untreated, it can cause fatal hypertensive crisis, stroke, myocardial infarction, arrhythmia, or catecholamine cardiomyopathy.
• It is a classic anesthetic trap: an unrecognized pheochromocytoma can precipitate a lethal catecholamine surge on induction of anesthesia or during unrelated surgery.

The tumor is famously described by the "Rule of 10s" — roughly 10% extra-adrenal, 10% bilateral, 10% malignant, 10% pediatric, and (in the classic teaching) 10% familial. Modern genetics has revised the familial figure upward toward 40%, but the mnemonic remains a durable teaching scaffold.

The Mechanism: How the Catecholamine Storm Is Built

Chromaffin cells synthesize catecholamines through a defined enzymatic cascade. Tyrosine → L-DOPA (via tyrosine hydroxylase, the rate-limiting step) → dopamine → norepinephrine (via dopamine β-hydroxylase). The final step, norepinephrine → epinephrine, requires phenylethanolamine-N-methyltransferase (PNMT), an enzyme induced by high local cortisol from the surrounding adrenal cortex. Because only intra-adrenal tumors sit in that cortisol bath, adrenal pheochromocytomas can make epinephrine, whereas extra-adrenal paragangliomas typically make only norepinephrine or dopamine.

Downstream, the released catecholamines act on adrenergic receptors:

• α1 → vasoconstriction → hypertension.
• β1 → increased heart rate and contractility → palpitations, tachyarrhythmia.
• β2 → tremor, hyperglycemia, and paradoxical vasodilation.

Crucially, catecholamines are continuously metabolized inside the tumor by catechol-O-methyltransferase into metanephrine and normetanephrine — released steadily even between symptomatic paroxysms. This constant leak is exactly why metanephrines, not the parent catecholamines, are the superior diagnostic marker.

Clinical Presentation and the Classic Triad

The textbook clue is the classic triad of episodic Headache, Sweating (diaphoresis), and Palpitations/Tachycardia — remembered as the "PHE" or "H-S-P" triad. When all three occur together with hypertension, the specificity for pheochromocytoma approaches 90%.

The hallmark is paroxysms: abrupt spells lasting minutes, with a rapid rise and slow fall in symptoms. Between attacks the patient may look entirely well.

• Hypertension — sustained, paroxysmal, or (classically) both; ~10% are normotensive.
• A sense of impending doom, anxiety, pallor (not flushing — vasoconstriction predominates), tremor, and weight loss.
• Orthostatic hypotension despite hypertension — from volume depletion and downregulated receptors — is a subtle but valuable clue.

Paroxysms can be triggered by abdominal palpation, exercise, micturition (bladder paraganglioma), anesthesia induction, foods rich in tyramine, or drugs such as metoclopramide, unopposed beta-blockers, and tricyclic antidepressants. The "5 P's" — Pressure (BP), Pain (headache), Perspiration, Palpitations, Pallor — capture the syndrome concisely.

Diagnosis: Biochemistry First, Then Imaging

Diagnosis proceeds in two steps: prove the catecholamine excess biochemically, then localize the tumor. Do not image first — an incidentaloma is not a pheochromocytoma until the biochemistry confirms it.

Biochemical testing (the cornerstone):

• Plasma free metanephrines and normetanephrine — sensitivity ~97–99%, specificity ~93%. The high sensitivity means a normal result essentially excludes the disease. Draw supine after a 30-minute rest to reduce false positives.
• 24-hour urinary fractionated metanephrines and catecholamines — highly specific confirmatory test.
• A value greater than 4× the upper limit of normal is nearly diagnostic; borderline elevations warrant a clonidine-suppression test.

Localization (only after positive biochemistry):

• CT or MRI of the abdomen/pelvis — most tumors are adrenal; classic MRI shows a bright "lightbulb" T2 signal.
• Functional imaging — ¹²³I-MIBG scintigraphy or, increasingly, ⁶⁸Ga-DOTATATE PET (superior, especially for SDHB metastatic disease) to find extra-adrenal or multifocal tumors.

Because up to 40% are hereditary, germline genetic testing (RET, VHL, NF1, SDHx, MAX, TMEM127) is now recommended for essentially all patients.

Management: Why Alpha-Blockade Must Come First

The definitive treatment is surgical resection (usually laparoscopic adrenalectomy), but the pre-operative pharmacologic sequence is a board-favorite because getting it wrong can be fatal.

Step 1 — Alpha-blockade, always first. Start phenoxybenzamine (irreversible, non-selective α-blocker) or a selective α1-blocker such as doxazosin 7–14 days before surgery. This blocks α1-mediated vasoconstriction, controls blood pressure, and allows the contracted intravascular volume to re-expand.

Step 2 — Beta-blockade, only after adequate alpha-blockade. Add a β-blocker (e.g., propranolol, metoprolol) to control reflex tachycardia.

• Never give a beta-blocker first. Blocking β2-mediated vasodilation while α1 vasoconstriction runs unopposed causes a catastrophic surge in blood pressure — unopposed alpha stimulation and potential hypertensive crisis.

Adjuncts include liberal salt and fluid loading to reverse volume depletion, and metyrosine (blocks tyrosine hydroxylase, reducing catecholamine synthesis) in refractory cases. During surgery, intraoperative surges are managed with phentolamine, nitroprusside, or magnesium. Post-resection hypotension and hypoglycemia are anticipated as catecholamine drive abruptly ceases.

Mimics, Pitfalls, and the Do-Not-Miss Points

Pheochromocytoma is a great imitator, and several traps recur on wards and exams:

• Mimics: panic disorder, thyroid storm (check TSH), carcinoid syndrome (flushing predominates here, unlike the pallor of pheo), hypoglycemia, cocaine/amphetamine or MAOI-tyramine crises, and "pseudopheochromocytoma" of severe anxiety.
• Catecholamine cardiomyopathy: a takotsubo-like, often reversible cardiomyopathy from catecholamine toxicity — a key cause of acute heart failure or shock in an undiagnosed patient.
• The anesthesia trap: induction can precipitate a lethal surge; screen before elective surgery in high-risk patients.
• Drug pitfalls: metoclopramide, glucagon, IV contrast (older concern), tricyclics, and — most importantly — beta-blockers before alpha-blockade.

Metastatic disease is defined by chromaffin tissue in sites where it does not normally occur (e.g., bone, liver, lymph nodes) — there is no reliable histologic marker of malignancy, so behavior, not biopsy, defines it. SDHB mutations carry the highest metastatic risk. Lifelong biochemical surveillance follows resection because of recurrence and hereditary syndromes.

Biochemical and clinical clues to the main hereditary pheochromocytoma syndromes (~40% of PPGL are now hereditary, revising the classic "10% familial")

Gene / Syndrome	Location & behavior	Catecholamine profile	Malignancy risk
RET (MEN2A/2B)	Adrenal, often bilateral; benign	Epinephrine-predominant (adrenergic)	Low
VHL (von Hippel–Lindau)	Adrenal, may be bilateral; benign	Norepinephrine-predominant (noradrenergic)	Low
NF1 (neurofibromatosis type 1)	Adrenal, usually solitary	Epinephrine/mixed	Low
SDHB	Extra-adrenal (paraganglioma), abdominal	Norepinephrine / dopamine	High (~30–70% metastatic)
SDHD	Head & neck paraganglioma; parent-of-origin	Often non-secretory or dopaminergic	Low–moderate